Fortive Corporation (NYSE: FTV) — A 2% Grower Wearing a Compounder’s Multiple, Buying Back the Difference

Independent fundamental research. Report date: 2026-07-04. All figures are continuing-operations (“New Fortive”/RemainCo) unless noted; the Precision Technologies segment was spun off as Ralliant Corporation on June 28, 2025.

⚡ Claude’s Take

This block is the author’s own independent, subjective opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The detailed analysis that follows takes no position and carries no price target; that discipline is intact everywhere except inside this fenced block.

Verdict: HOLD / quality-at-a-full-price. Not a short. Accumulate on weakness toward the high-$40s–low-$50s (~16–18x forward adjusted EPS), not here at ~21x. Conviction: medium. Tag: “A 2% grower buying back the difference.”

Post-spin Fortive is a genuinely good business wearing a full price. The operating quality is real — 63.5% gross margins, ~30% adjusted EBITDA margins, 100%+ free-cash-flow conversion, two durable moats (Fluke’s brand-and-distribution captivity and ASP Sterrad’s installed-base + FDA switching costs), and the Fortive Business System as a demonstrated margin engine. But the growth is not: this is a ~2–3% organic grower whose headline “double-digit adjusted-EPS growth” is manufactured largely by retiring >10% of the share count since the July-2025 spin, funded by rising 2.4x leverage, while GAAP returns on capital sit near or below the cost of capital because ~$9.5B of acquisition goodwill (81% of assets) drags consolidated returns down. Two quieter props hold up the earnings algorithm: a sub-12% effective tax rate and an amortization add-back that lets management be paid 60% on an EPS metric it can partly buy. The market is paying ~21x forward adjusted earnings and ~17x EV/EBITDA for that algorithm. The honest read on valuation is full, not extreme — the “richest-ever” 99.9th-percentile P/E and P/S screens are contaminated by the spin shrinking the sales base, and against true compounder peers (Roper, Veralto, Ametek) Fortive is actually mid-pack on EV/EBITDA and at the low end on forward P/E. So it is not a short: quality plus buyback support plus a not-crazy multiple. But the easy money has been made — the stock has mean-reverted +36% off a washed-out post-spin low and now sits at its post-spin high, with the compounder re-rating largely priced before ~3% organic has proven durable. I would rather own it where the company and its own CFO were buying (~$47–54) than chase it at 21x on a 2% top line.

What flips me bullish: two-plus quarters of normalized organic growth durably ≥4% (data-center Fluke pull-through and the software/AI attach actually inflecting the organic rate), which would convert the buyback story into a genuine compounder story. What flips me bearish: normalized organic slipping below 2% and the buyback pace halving as leverage hits the ~3.0x practical ceiling and/or the tax rate normalizing toward the low-20s — any two of which would expose a mid-single-digit EPS grower paying a low-double-digit-grower’s multiple.

📈 Stock Price Action — Five-Year Event Map

Factual five-year price history for context. Price moves are Facts; attributed drivers are Interpretation. No price target, no support/resistance, no chart-pattern reading. The critical caveat below: the AZI price series is spin-adjusted, so pre-June-2025 prices are marked down ~25% for the Ralliant distribution — a mechanical adjustment, not a repricing.

Over the trailing ~60 months Fortive has effectively become two different stocks, and the tape must be read through that lens. On the spin-adjusted series, the shares round-tripped from roughly $53 (mid-2021) → a $64.31 adjusted peak (Feb 2024) → a $46.09 low (Aug 2025) → ~$62.65 today — within ~1% of the $63.34 52-week high and just shy of the spin-adjusted 2024 peak. On an unadjusted basis the pre-spin combined company traded as high as ~$80 (Nov 2021); the ~$85 unadjusted print of early 2024 corresponds to that $64.31 adjusted high. The single most important distinction: the ~25% drop across June 2025 was mechanical (the Ralliant separation), not a repricing — holders received Ralliant shares of offsetting value. “New Fortive” alone is now +36% off its August-2025 low.

Cycle narrative. Events 1–4 are the pre-spin combined entity — a classic quality-industrial that re-rated hard in 2023–24 on FBS margin delivery, then rolled with the short-cycle in 2024. Event 6 is load-bearing for any valuation comparison: the June-2025 “drop” is the Ralliant distribution, not weakness — mistaking it for a decline overstates New Fortive’s fragility. Events 7–8 are the real signal: a washed-out post-spin low near $46 (forced/rebalancing selling into an untested standalone) followed by a sharp +36% re-rating as management strung together three beats, drove double-digit adjusted-EPS growth, and retired >10% of the share count. The stock now sits essentially at its post-spin high, having nearly reclaimed the spin-adjusted 2024 peak.

1. Executive Summary

Fortive is the highest-quality third of a business that has spent a decade dismantling itself — spun from Danaher in 2016, it separated its diagnostics-and-retail businesses as Vontier in 2020 and its Precision Technologies segment as Ralliant in June 2025. What remains is a $4.16B-revenue, two-segment industrial-and-healthcare technology company: Intelligent Operating Solutions (IOS, 69% of revenue — Fluke test instruments, facility/asset-lifecycle and EHSQ software, gas detection) and Advanced Healthcare Solutions (AHS, 31% — ASP/Sterrad sterilization, surgical-instrument tracking, radiation dosimetry, clinical software). It is capital-light (2.5% capex intensity), high-margin (63.5% gross, ~30% adjusted EBITDA), and highly cash-generative (~$930M FCF, 100%+ conversion), run on the Danaher-derived Fortive Business System.

The investment tension is simple and sits squarely between the two halves of the value-creation equation. On business quality, Fortive earns a genuine, if uneven, pass: two durable moats (Fluke’s brand/distribution captivity; ASP Sterrad’s razor/razor-blade + FDA switching costs), a durable-but-slow regulatory-service franchise (Landauer), and a portfolio of adequate-but-contestable software assets. On growth, it does not: organic revenue grew just +1.7% in 2025 (price +2.2%, volume −0.6%), and management guides to only 2–3% core growth for 2026. The reconciliation between a 2% top line and the “double-digit adjusted-EPS growth” narrative is the crux of this memo: it is delivered by retiring >10% of the share count since the spin (funded by rising 2.4x leverage and the Ralliant dividend), a sub-12% tax rate, and an amortization add-back that lifts reported adjusted EPS to $2.71 (FY2025) from a GAAP continuing-ops figure of just $1.59. Consolidated GAAP returns on capital sit near or below the ~8% cost of capital because ~$9.5B of acquisition goodwill (81% of assets) prices the businesses richly — the problem is the price paid, not the businesses.

On valuation, the honest verdict is full, not extreme. At ~$62.65 the stock trades at ~21x forward adjusted EPS and ~17x TTM EV/EBITDA — mid-pack on EV/EBITDA and at the low end on forward P/E versus true compounder peers (Roper, Veralto, Ametek). The AZI 99.9th-percentile “richest-ever” P/E and P/S screens are contaminated by the spin (which shrank the sales base ~28% and depressed GAAP EPS); the cleaner 79th-percentile P/B reads “rich, not extreme.” The market is underwriting the algorithm — 2–3% organic + 50–100 bps annual margin expansion + ~5% annual share shrink → low-double-digit EPS growth, sustained, with no multiple compression. The pivotal, falsifiable question for the next several quarters is whether normalized organic growth holds ≥3%; everything in the multiple leans on it. Governance flags — a comp scorecard with no return-on-capital metric and <1% insider ownership — temper the grade, partially offset by the new CFO’s ~$1M open-market purchase near the post-spin low.

2. Business Overview

Fortive Corporation is what remains after the third leg of a serial de-conglomeration that began when it was itself spun out of Danaher in July 2016. On June 28, 2025, Fortive separated its Precision Technologies segment into an independent public company, Ralliant Corporation, in a tax-free spin-off. What is left — the entity this memo analyzes — is a two-segment industrial-and-healthcare technology company headquartered in Everett, Washington, with roughly 10,000 employees across ~50 countries and FY2025 revenue of $4,159.1M from continuing operations (2024: $4,080.9M; 2023: $3,913.9M). All figures below are continuing-operations, i.e., RemainCo only.

Segment 1 — Intelligent Operating Solutions (IOS): $2,856.3M, 68.7% of revenue (Fact; 10-K Note 16). This is the larger and higher-quality half, materially bigger than the “~60%” framing that circulated pre-spin — post-spin Fortive is nearly 70% IOS. IOS sells professional instruments, facility/asset-lifecycle software, and connected-worker safety solutions under six brands: FLUKE (handheld electrical test & measurement — the crown jewel, ~40% of the whole company), ACCRUENT, GORDIAN, SERVICECHANNEL (facility and asset-lifecycle / IWMS software), INDUSTRIAL SCIENTIFIC (portable gas detection / connected-worker safety), and INTELEX (EHSQ compliance software). End users are electricians, network engineers, EHS professionals, facility managers, and first responders. IOS carries a 25.8% GAAP segment operating margin and 65.9% gross margin — genuinely attractive economics.

Segment 2 — Advanced Healthcare Solutions (AHS): $1,302.8M, 31.3% of revenue (Fact; 10-K Note 16). AHS supplies hospital-workflow solutions under ADVANCED STERILIZATION PRODUCTS (“ASP” / STERRAD low-temperature sterilization), CENSIS (CensiTrac surgical-instrument tracking), FLUKE BIOMEDICAL, LANDAUER (radiation dosimetry service), PROVATION (clinical/GI productivity software), RAYSAFE and INVETECH. AHS reports a 10.6% GAAP segment operating margin — but that number is misleading. Amortization of acquired intangibles runs 13.8% of AHS sales versus 6.6% at IOS; add it back and AHS operates at a mid-20s cash margin. AHS gross margin is 58.1%. The optically thin GAAP margin is an artifact of how expensively these businesses were bought, not of the businesses’ underlying economics.

Revenue model and mix. Fortive is a razor/razor-blade-plus-software business. It sells (i) durable instruments and capital equipment (Fluke meters, Sterrad sterilizers), (ii) high-margin consumables pulled through the installed base (Sterrad sterilization cassettes and chemical/biological indicators), (iii) recurring services (Landauer dosimetry programs, calibration, biomedical service), and (iv) subscription software (Accruent, Gordian, ServiceChannel, Intelex, Censis, Provation). Management stated at its June 2025 Investor Day that RemainCo is “~50% recurring revenue” (interpretation / management claim — treat as hypothesis, not evidence). This is not corroborated in the 10-K. The only revenue-nature split the filing discloses is products-and-software $3,341.3M (80.3%) versus services $817.8M (19.7%) — software is lumped with products, so the filing cannot confirm the 50% figure. Services alone are ~20%. The “~50% recurring” claim therefore rests on management’s internal definition (subscriptions + consumables + service) and should be treated as a hypothesis to validate, not a fact. Corroborating evidence that the direction is right: remaining performance obligations (contracted, not-yet-recognized revenue) stand at $840.7M, “the majority related to subscription-based software contracts” (10-K), and management states recurring revenue grew faster than total revenue in both segments through 2025–26 (Open Question: recurring % and net-revenue-retention by segment remain undisclosed).

End markets and geography (Fact; 10-K disaggregation, FY2025): Healthcare $1,280.5M (essentially all of AHS), Industrial & Manufacturing $1,198.7M, Energy & Infrastructure $687.6M, Government $350.6M, Retail $315.7M (facility software for multi-site operators), Other $326.0M. The company is US-centric — North America is 60% of sales ($2,491.1M); the balance is APAC $730.1M (18%), EMEA $725.8M, and LatAm $212.1M.

A capital-light business dressed in a heavy balance sheet. Capital expenditure was only $105.1M, or 2.5% of sales — a low-capital-intensity, high-gross-margin model. Yet reported ROIC is just 5.3%, because the balance sheet is loaded with goodwill and intangibles from Danaher-style serial M&A. That 5.3% measures what Fortive paid for its businesses, not the incremental economics of running them; the moat, if it exists, must show up as high cash return on tangible and incremental capital (see Financial Quality), which the 2.5% capex intensity and 63.5% gross margin strongly imply is high.

Verdict. Post-spin Fortive is a capital-light, brand-and-software-anchored industrial-healthcare compounder, ~69% weighted to the higher-quality IOS segment. The spin’s stated purpose — a higher-margin, higher-recurring “quality” RemainCo — is directionally credible on capital-intensity and gross margin, but two cautions stand: (1) the marquee “~50% recurring” figure is a management definition the 10-K does not substantiate (filed services = 20%), and (2) AHS, a third of revenue, is the structurally slower-growing and optically weaker half. This is a good business, but the label needs auditing, not adopting.

3. Industry Dynamics

Fortive competes across four distinct market structures, and they are not equally attractive. I assess each, then render an aggregate verdict and locate the portfolio in Marathon capital-cycle terms.

1. Handheld electrical test & measurement (Fluke). This is Fortive’s best industry. The digital-multimeter market is small (~$1.05B in 2024, growing ~6% toward ~$1.77B by 2033 — Grand View Research), which is precisely why it is defensible: it is too small and too brand-driven to attract well-capitalized entrants, yet large enough to sustain a dominant incumbent. Competition exists (Keysight, Tektronix, Klein Tools, HIOKI, plus low-cost Asian brands UNI-T/Rigol), but the category is defined by safety-criticality, ruggedness, and tradesperson brand loyalty — an electrician trusts the meter with their life and buys the name they were trained on. Barriers are brand and distribution, not technology. Structurally good.

2. Facility / asset-lifecycle & EHSQ software (Accruent, Gordian, ServiceChannel, Intelex). The weakest industry structurally. This sits inside the fragmented IWMS / EAM / CMMS / EHSQ complex (IWMS alone ~$9.8B in 2023 → ~$12.1B by 2027). Growth is healthy, but so is competitive intensity: IBM Maximo, Nuvolo, Brightly (Siemens), eMaint, Fiix, MaintainX, UpKeep and dozens of niche vendors all contest the space; no single player dominates. Fortive’s edge here is account-level workflow embedding and switching costs, not category leadership — the Accruent/ServiceChannel integration is itself a defensive response to a crowded field. Structurally average; contestable.

3. Portable gas detection & connected-worker safety (Industrial Scientific). A regulation-underpinned niche (OSHA/EU confined-space and industrial-hygiene rules mandate gas monitoring). Competitors are serious — Honeywell, MSA Safety, Dräger — so this is an oligopoly of well-resourced players. Regulation creates a durable demand floor and the shift to connected/subscription monitoring adds recurring revenue, but pricing power is checked by credible rivals. Structurally good, competitively contested.

4. Medical low-temperature sterilization & instrument tracking (ASP, Censis). A structurally attractive medical niche. The low-temperature sterilization market grows toward ~$5.07B by 2030 (vaporized-hydrogen-peroxide ~9.2%). It is a consolidated oligopoly: STERIS (V-PRO), Getinge, and ASP (Sterrad) together hold ~45% share, with ASP ~27.6% of the advanced-sterilization niche. Barriers are high — FDA 510(k) clearance, validated hospital protocols, and installed-base lock-in. The offset: Fortive faces two larger, focused competitors (STERIS is a pure-play sterilization leader), and FY2025 exposed demand risk — AHS volume fell on “reduced demand for sterilization equipment … due to recent changes in healthcare policy” (10-K MD&A). Structurally good but slow-growing and policy-exposed.

5. Radiation dosimetry (Landauer). A regulatory-mandated recurring-service oligopoly — occupational radiation monitoring is legally required for healthcare/industrial/nuclear workers. The top-five vendors (Mirion, Landauer, Thermo Fisher, Fuji, Fortive) hold ~55% of revenue. The service model (badges issued, worn, returned, analyzed, reported) is inherently recurring and sticky, but the market is low-growth and Mirion is consolidating aggressively (RDC acquisition, 2024). Structurally good, low growth.

Aggregate verdict and capital-cycle read. Structurally good on balance, with one soft spot. Four of five markets have real barriers — brand (Fluke), regulation (Industrial Scientific, Landauer, ASP), and installed-base/switching-cost lock-in (ASP, software) — and low capital intensity across the board. The exception is the fragmented asset/EHSQ software market, where differentiation is thinner. In Marathon capital-cycle terms, none of these industries is in a classic capital-inflow-driven return-destruction phase: they are mature, oligopolistic or brand-fragmented niches where supply is disciplined precisely because the addressable pools are too small to lure large new entrants (Fluke, dosimetry, sterilization). The one area where capital is flowing — B2B facility/asset/EHSQ software — is exactly where Fortive’s moat is weakest. The read is favorable, but the growth engine and the moat are not perfectly aligned: the most defensible franchises (Fluke, ASP, Landauer) are also the slowest-growing, while the fastest-growing area (software) is the most contested.

4. Competitive Position

Fortive’s moat is brand-by-brand, not corporate-wide, and it ranges from genuinely durable to merely adequate. Assessing each through the Greenwald taxonomy (supply/cost advantage; demand/captivity; economies-of-scale-plus-captivity):

Fluke — the strongest moat: an intangible brand-and-distribution advantage (demand captivity). Fluke is the leader in handheld electrical test “by a country mile” (trade press). The mechanism is textbook customer captivity via brand and habit in a safety-critical, low-ticket, high-consequence category: a professional’s meter is a trust-and-safety purchase, standardized through training and reinforced by a decades-old reputation for ruggedness and accuracy. Global distribution reach compounds it. Tellingly, Fortive brackets its own franchise — it owns the value brands Amprobe and Extech that would otherwise undercut Fluke, a classic good/better/best moat defense. The financial fingerprint is IOS’s 65.9% gross margin and 25.8% segment operating margin. This is a real, durable moat. Verdict: durable.

ASP / Sterrad — the second-strongest: installed-base captivity plus regulatory switching costs (economies-of-scale-plus-captivity). Sterrad is the razor/razor-blade archetype: hospitals buy the sterilizer (razor) and are then locked into ASP’s proprietary hydrogen-peroxide cassettes and chemical/biological indicators (blades) for the machine’s life. Two switching-cost layers reinforce it: (1) FDA 510(k) clearance ties a validated sterilization cycle to specific consumables and load configurations, so a hospital cannot freely substitute a rival’s chemistry without revalidation and infection-control risk; and (2) sterile-processing staff are trained and credentialed on the installed platform. ASP holds ~27.6% of the advanced-sterilization niche within a ~45% top-three oligopoly with STERIS (V-PRO) and Getinge. The caution is that STERIS is a larger, focused pure-play, and FY2025 exposed cyclicality (equipment demand fell on healthcare-policy shifts). Verdict: durable moat, but slower-growing and facing two credible peers.

Landauer — regulatory-mandated recurring service (demand captivity + switching costs). Occupational dosimetry is legally required; Landauer supplies the badges, reads them, and files the compliance reports. Once a customer is enrolled with its historical dose records and reporting integrations, switching to Mirion or Thermo Fisher means migrating a compliance system of record — high friction for a low-cost, mission-critical service. Landauer is a top-two vendor in a ~55%-concentrated top five. The offset: low market growth and Mirion’s aggressive consolidation. Verdict: durable but low-growth.

Software (Accruent, Gordian, ServiceChannel, Intelex, Censis, Provation) — real but shallower switching costs in a contestable market. These are genuine recurring-revenue franchises with standard SaaS stickiness — data, workflows, integrations, and user training embedded in operations. But this is an order of magnitude weaker than the Fluke or ASP moats: the IWMS/EAM/EHSQ market is fragmented and crowded (IBM Maximo, Nuvolo, Brightly, eMaint, Fiix, MaintainX), and no Fortive software brand is a category king. Gordian’s construction-cost database (RSMeans) is the one genuinely proprietary data asset with a data-network flavor. Open Question: net revenue retention is not disclosed in the 10-K — the SaaS-moat claim cannot be quantified from filings. Verdict: adequate switching-cost moats, not dominant positions.

Pressure-testing FBS as a moat. Management centers its narrative on the Fortive Business System (FBS) — the Danaher-derived kaizen/lean operating toolkit. FBS is a real and valuable operating capability: it shows up in the ~105 bps of tariff mitigation and the productivity gains cited in the 2025 margin bridge. But FBS is not a customer-facing moat. It does not raise a customer’s switching cost or captivity; it is an internal cost-and-execution discipline that competitors (STERIS, Honeywell, every other lean operator) can and do replicate. Under the Greenwald test — a moat is only a moat if a financial outcome would deteriorate without it and a competitor cannot copy it — FBS fails the “cannot be copied” leg. It is a genuine source of margin and capital-allocation quality, but it should be underwritten as management quality, not competitive advantage.

Verdict. Durable advantage — but concentrated and uneven, not portfolio-wide. Fortive owns two genuinely durable moats (Fluke; ASP Sterrad), one durable-but-low-growth regulatory-service franchise (Landauer), and a portfolio of adequate-but-contestable software businesses. The strongest moats are also the slowest-growing; the fastest-growing (software) sit in the most crowded market. FBS is a real edge but operational, not competitive. Reported ROIC of 5.3% dramatically understates the underlying franchise economics (goodwill-loaded, 2.5% capex, 63.5% gross margin) — the businesses earn high cash returns on tangible capital — but the investor must be clear-eyed that the durability is anchored in Fluke and ASP, not spread evenly across the whole.

5. Growth History and Forward Opportunities

Historical growth — modest organic, historically M&A-augmented. On a continuing-operations (post-spin) recast basis, revenue moved $3,913.9M (2023) → $4,080.9M (2024) → $4,159.1M (2025), i.e. ~+4.3% then ~+1.9% reported. Decomposed, FY2025’s growth was +2.2% price and −0.6% volume, or +1.7% core — the entire top line came from pricing (much of it tariff pass-through), with unit demand actually contracting (Fact; 10-K MD&A). The old Fortive was a serial acquirer; RemainCo’s guided algorithm is more honest about the base business: FY2026 core (organic) growth of 2–3%, “trending toward the upper end” (Fact; Q1’26 call). Q1’26 printed +5% consolidated core, but management explicitly flagged ~150 bps as an extra-selling-days tailwind, putting normalized organic at ~3.5%. This is the central growth reality: Fortive is a ~mid-single-digit organic grower at best, not a double-digit one.

Segment composition and trajectory. Growth decelerated across both segments in 2025: IOS core slowed from +3.5% (2024) to +2.1% (2025); AHS from +6.1% to +0.8%, the latter hit by soft demand for sterilization capital equipment and biomedical test as hospital capital budgets tightened. In Q1’26 the picture improved at the margin — IOS core ~5% (normalized ~4%), AHS core ~6% (normalized ~3%, after a large selling-days benefit on consumables/software). Growth leadership came from Facilities & Asset Lifecycle (FAL), led by ServiceChannel, which grew faster than the IOS segment, plus gas-detection hardware-as-a-service share gains and Fluke order strength (book-to-bill >1).

Recurring-revenue mix — the quality upgrade. The most credible forward driver: recurring revenue grew faster than total revenue in both segments through 2025–26, and software revenue grew “nicely ahead” of the company. This is the mechanism behind the post-spin “higher-quality compounder” pitch — a mix shift toward subscription/services that should modestly lift durability, pricing, and margins over time (Interpretation).

Forward opportunities, weighed honestly. (1) Data-center O&M for Fluke — the CertiFiber Max fiber-tester launch is pulling through power-quality, battery, imaging, and calibration products; management frames ongoing operations/maintenance (not just build-out) as the durable leg (claim; magnitude an Assumption). This is the single most important AI-adjacent narrative behind the recent re-rating. (2) Software + AI attach — ServiceChannel AI work-order insights, Provation Mirror voice documentation, AI-enhanced Fluke releases; framed as a growth accelerant (management hypothesis, not yet visible in the organic rate). (3) FBS margin expansion — the 50–100 bps/yr adjusted-EBITDA-margin algorithm is a demonstrated capability. (4) Healthcare-capital recovery — low-temperature-sterilization capital “improving modestly” off a 2025 trough, with made-in-region China/India tailwinds and a European STERRAD Ultra GI launch. (5) Bolt-on M&A — a rebuilt engine (new corp-dev head; June-2026 UV Smart deal), but not yet a needle-mover.

Verdict — modest-quality growth, improving at the margin. The growth is durable but structurally low (~2–3% organic), sitting in mature short-cycle industrial and pressured healthcare-capital markets. What redeems the quality score is the composition trend — recurring and software growing faster than the whole, plus a real FBS margin engine — which makes the growth more defensible than a 2–3% number suggests. But it is not high-quality growth in the compounding sense: the headline double-digit adjusted-EPS growth is manufactured largely by buybacks and margin, not by volume. Absent acceleration in the software/data-center legs, this is a low-growth business that must earn its multiple on quality and capital return, not on organic expansion.

6. Financial Quality

Revenue and margin structure — GAAP vs. adjusted, and the amortization wedge. Gross margin is a healthy 63.5% (down 70 bps YoY on tariff and mix), evidencing genuine pricing power and an asset-light, instrument-and-software mix. But GAAP operating margin is only 17.3% ($720.2M), while management’s adjusted operating margin is ~26% and adjusted EBITDA margin ~29.6% ($1,233M; note the aggregator’s unadjusted EBITDA is $1,157.8M / 27.8%). The ~9-point GAAP-to-adjusted gap is almost entirely amortization of acquired intangibles — $367.5M, or 8.8% of sales — the accounting unwind of a decade of acquisitions. This is the defining feature of a Danaher-heritage serial acquirer: GAAP earnings are structurally depressed by the amortization of the very deals that built the company. The add-back is legitimate for cash purposes (amortization is non-cash), but it is a permanent reminder that GAAP profitability understates cash economics while reported returns on capital overstate the quality of the price paid.

The GAAP-to-adjusted EPS bridge is clean and worth stating precisely (Q4’25 release): GAAP continuing-ops EPS $1.59 + acquisition-intangible amortization $1.10 + acquisition/divestiture/separation items $0.13 + discrete restructuring $0.10 − tax effect $0.20 = adjusted diluted EPS of $2.71 (FY2024: $2.41; +12.4%). Fully 98% of the $1.12 wedge is amortization. Critically, stock-based compensation ($116.8M) is not added back — an honest choice many peers do not make. The FY2026 guide is adjusted EPS $2.90–$3.00 (+7% to +11%) on core growth of 2–3% and reported revenue ~$4.3B.

A quality-of-earnings flag on tax. The effective tax rate was 11.5% (2025), 4.7% (2024), 5.7% (2023) — extraordinarily low versus the 21% U.S. statutory rate, driven by foreign-earnings mix and credits. This flatters both GAAP and adjusted EPS. Were the rate to normalize toward the low-20s — a live risk given the OBBBA and OECD Pillar Two “Side-by-Side” regime the company flags — adjusted EPS would fall on the order of 12–15%, all else equal (Interpretation). The sustainability of a sub-12% rate is a genuine open question and one of the larger swing factors in the earnings algorithm.

Free cash flow quality and conversion — the best part of the story. Continuing-operations operating cash flow was $1,035.7M; capex just $105.1M (2.5% of sales); free cash flow $930.6M (FY2024: $942.4M — notably down YoY despite higher revenue, on separation cash costs and higher capex). FCF converts at 103% of adjusted net earnings and ~175% of GAAP continuing net income. On the quality-of-earnings test — is net income diverging from cash? — the answer is favorable: cash exceeds GAAP earnings (OCF $1,035.7M vs. GAAP continuing net income $532.7M), the gap explained by $437.6M D&A and $116.8M non-cash SBC. There is no working-capital-fueled earnings mirage; if anything, GAAP understates the cash. (Note: total-company OCF of $1,083.2M in the statement includes a half-year of Ralliant discontinued operations and should be discarded for run-rate.)

SBC and dilution. SBC of $116.8M rose 30% YoY (separation-driven re-striking of equity awards); it equals 22% of GAAP continuing net income and 11% of OCF — material but not egregious, and a real cost adjusted EPS correctly bears. Crucially, buybacks overwhelmed option dilution: shares outstanding fell from 341.2M to 313.4M over 2025, so per-share metrics improved despite the higher grant load.

The ROIC question — the honest answer. Reported ROIC of ~5.3% is the number bears will quote, and it is real: on a GAAP invested-capital base of ~$9,291.6M, NOPAT normalized at 21% tax (~$569M) implies ROIC ~6.1% — below an ~8% cost of capital. But that base carries $9,486.7M of goodwill and intangibles — 80.8% of assets. Two adjustments reframe it. First, adding back amortization lifts “cash NOPAT” to ~$859M, or ~9.2% on the same base — roughly at WACC. Second, and more revealingly, tangible invested capital is negative (goodwill/intangibles exceed total invested capital): the operating businesses run on essentially zero tangible capital — low PP&E, negative working capital via deferred subscription revenue — so the incremental cash return on tangible capital is effectively unbounded. The synthesis is the key judgment: these are genuinely good, asset-light businesses (63.5% gross margins, ~30% adjusted EBITDA, 100%+ FCF conversion), but Fortive paid rich multiples to acquire them, and the ~$9.5B of goodwill that price created drags consolidated returns down to approximately the cost of capital. The problem is not the businesses; it is the price paid for them.

Balance sheet. Net debt is $2,830.5M (2.4x GAAP EBITDA, ~2.3x adjusted), with ~9.6x interest coverage — comfortably investment-grade, inside the 3.5x net-leverage covenant (stepping to 4.0x after a large acquisition), backstopped by a $2.0B undrawn revolver. The stack is plain-vanilla senior unsecured notes plus ~$650M–$900M of commercial paper. Tangible book equity is deeply negative — roughly −$9.68/share — because book equity is entirely goodwill. For an asset-light serial acquirer this is normal and not a distress signal: with 9.6x coverage and $930M of FCF, the negative tangible equity is an accounting artifact of the M&A model, not a solvency concern. The one thing to watch is refinancing cost: the 2026 maturities were refinanced in May 2026 with $1.1B of new notes at 4.750% (2031) and 5.250% (2036) — well above the retired 3.15%/3.7% coupons — pushing guided FY2026 net interest to ~$135M.

Verdict — do economics improve with scale? Operationally, yes; on returns to capital, only to a point. The businesses are structurally excellent — asset-light, high-margin, cash-generative, with pricing power and FBS-driven operating leverage. But the serial-acquisition model has embedded ~$9.5B of goodwill at prices high enough that consolidated cash returns sit around the cost of capital, and reported GAAP returns sit below it. The earnings are of good cash quality (cash exceeds GAAP; conversion >100%), with two honest caveats — a very low tax rate flattering the whole P&L, and a GAAP figure so amortization-burdened that only the adjusted numbers are analytically useful. This is a high-quality cash machine whose scale benefits accrue to margins and free cash flow, not to headline return-on-capital.

7. Capital Allocation

The model, and a telling three-year pause. Fortive is a Danaher clone — spun out in 2016, running FBS, built by acquiring instrument and vertical-software businesses and compounding them. The $9.5B of goodwill and intangibles is the fossil record of that engine: Accruent (~$2.0B, 2018), Gordian ($775M, 2018), Intelex/Censis/PrÜftechnik (~$1.2B, 2019), Advanced Sterilization Products (~$2.7B, 2019), ServiceChannel (~$1.2B, 2021) and Provation ($1.425B, 2021) — software and healthcare assets bought at rich multiples (broadly 4–6x sales, high-teens EBITDA). What is striking in the filings is that the M&A engine has been essentially dormant for three years: cash paid for acquisitions was $95.8M (2023), $3.6M (2024), $25.7M (2025). Management spent 2023–2025 preparing and executing the Ralliant separation and redeploying capital into its own stock instead. The engine is now restarting: in June 2026, ASP acquired a majority stake in UV Smart (a European UV-C disinfection company; terms undisclosed), and a new corporate-development head (Corbin Wahlberger) has been installed (Interpretation: signal of intent, not yet a sized commitment).

The Ralliant spin as a capital-allocation decision. The June 28, 2025 spin (one Ralliant share per three Fortive shares) was the marquee capital-allocation act, executed cleanly. Fortive extracted a $1.15B Ralliant Dividend plus cash proceeds and put it to disciplined use: $294M to redeem €252M of 3.7% 2026 notes, $421M to repay Euro/Yen term loans, and $483M to repurchase stock. Retained earnings fell $2.8B (to $5,428.5M), reflecting the carve-out distribution. The result is a higher-margin, more-recurring, more asset-light RemainCo with a delevered balance sheet — a defensible portfolio decision that concentrated Fortive on its better businesses.

The 2025 buyback — the real EPS engine. Fortive repurchased $1,610.1M of stock in 2025 (~30M shares at ~$53.67 average), of which $483M was funded by Ralliant proceeds. With $92.2M of dividends, total capital returned was ~$1.70B against $930.6M of FCF — the excess financed by the Ralliant dividend. Post-spin the pace was aggressive: ~$1.3B in H2 alone (~26M shares), retiring more than 10% of the share count since the spin. This is the mechanical source of the “double-digit adjusted-EPS growth” narrative: on 2–3% organic and ~$930M of FCF, a >10% reduction in share count does most of the per-share work. That is legitimate value creation if the stock is cheap — and the ~$53.67 average 2025 repurchase price (near the CFO’s own $47 purchase) looks reasonable against the current ~$62.65. But it is financial engineering that depends on a low price to stay accretive; buying back at ~21x forward adjusted earnings is a materially less obvious win than at 15x, and the pace is bounded by the 3.5x leverage covenant (~$1.5–2.0B of additional capacity at 2.4x today).

Dividend and debt management. The dividend is deliberately small — $0.24/year (~$0.06/quarter), ~17% of adjusted EPS, ~0.4% yield — the classic Danaher-heritage preference for buybacks and reinvestment over payout. Debt management is competent: the 2026 maturity wall was pre-refinanced in May 2026 and the revolver extended (third amended-and-restated credit agreement, March 2026), though the refinancing locks in higher coupons.

Incentives — the governance flag. The April-2026 proxy reveals a compensation scorecard entirely absent of any return-on-capital metric. The annual cash bonus is Adjusted EPS (60%) / Free Cash Flow (20%) / Core Revenue Growth (20%); the PSUs (50% of LTI) are 60% relative TSR vs. the S&P 500 (target 55th percentile) and 40% Core Revenue Growth over three years. No ROIC, ROE, or RONA hurdle appears anywhere (Interpretation). For a company whose identity is “disciplined capital allocation,” this is a real misalignment: management is paid 60% on Adjusted EPS — a metric that adds back the amortization of the acquisitions and is mechanically inflated by the buybacks — while never being held to a return on the capital those acquisitions consumed. ROIC surfaces in the proxy only as marketing, not as a pay lever. Reinforcing the concern, insider ownership is thin: all current directors and officers own <1% as a group; the largest individual holder is the departed CEO Jim Lico. Ownership guidelines were just raised (CEO 5x→6x salary), and say-on-pay passed at a middling 86.5%.

Insider behavior — one genuine signal. Against that low-ownership backdrop, the lone conviction data point is positive: new CFO Mark Okerstrom made an open-market purchase of 21,300 shares at $47.03 (~$1.0M) on August 1, 2025, just after the spin and near the post-spin low — real skin in the game from a fresh CFO. No other discretionary buying occurred; the rest of the Form 4 flow is routine grants, option exercises, and tax-withholding.

Verdict — has management allocated capital intelligently? Competent and shareholder-friendly, with governance caveats. The Ralliant spin was clean and value-focused; the balance sheet is well-managed; and the aggressive, sensibly-priced 2025 buyback is defensible. But two flags temper the grade: (1) the historical M&A that defines the company was priced richly enough that consolidated returns sit near WACC (see Financial Quality), and (2) the incentive structure and thin insider ownership give management every reason to keep buying back stock and reporting amortization-adjusted EPS growth, and no contractual reason to earn a return on incremental capital. The reset team (Soroye/Okerstrom) is unproven on the one thing that matters most for a serial acquirer — the price discipline of the next deals — and the UV Smart restart bears watching.

8. Changes and Headwinds — Last Two Years

The last twenty-four months reshaped the company more than any period since the Danaher spin. A material-event timeline and its thesis implications:

• Sep 4, 2024 — separation announced. Fortive announces the split into RemainCo (IOS + AHS) and Precision Technologies (later Ralliant). Strengthens the thesis’s clarity: management chose to concentrate on the higher-margin, more-recurring businesses.
• Jan 2025 / mid-2025 — leadership reset. Olumide Soroye (ex-CoreLogic; ran IOS from 2021 and AHS from Jan 2025) becomes CEO of RemainCo on separation, succeeding long-time CEO Jim Lico; Mark Okerstrom (ex-Expedia CEO) is CFO. A wholesale management reset — new, and unproven on capital-allocation price discipline (see Capital Allocation). Neutral-to-watchful.
• June 28, 2025 — Ralliant spin completes. $1.15B dividend to Fortive; proceeds used for debt paydown and buyback. Executes the portfolio decision cleanly; the ~25% price adjustment is mechanical, not fundamental (see the Stock Price Action section).
• H2 2025 — buyback acceleration. ~$1.3B repurchased, >10% of shares retired since the spin. The engine of reported EPS growth; sensible at ~$54 average, but leverage-bounded.
• Feb 4, 2026 — FY2025 results / FY2026 guide. Adjusted EPS $2.71 (beat), FY2026 guide $2.90–$3.00 on 2–3% core. Confirms the low-organic, buyback-levered algorithm.
• May 14, 2026 — $1.1B refinancing at 4.75%/5.25% (vs. retired 3.15%/3.7%). Raises net interest to ~$135M; a modest, structural headwind.
• June 24, 2026 — ASP/UV Smart bolt-on. M&A engine restarts; watch price discipline.

Standing headwinds. (1) Healthcare-capital softness — U.S. hospital capital budgets tightened on reimbursement/policy shifts, deferring Sterrad sterilizer and biomedical-test purchases; AHS core growth fell to +0.8% in 2025 (troughed Q2’25, improving since). (2) Tariffs — a ~100–150 bps gross-margin headwind, fully price-countermeasured on the bottom line, expected to dissipate as it laps in Q4’26; not meaningful to 2026 EPS per management. (3) Short-cycle industrial demand — Fluke (~40% of the company) is late-cycle-exposed; volume was negative in 2025. (4) Rising interest cost on refinanced debt. (5) AI-disintermediation debate around the vertical-software portfolio (Accruent/ServiceChannel/Provation) — management argues mission-critical, deeply-integrated systems of record are defensible; unproven.

Verdict. The structural changes (spin, mix upgrade) strengthen the quality of the franchise; the cyclical and cost headwinds (healthcare capital, short-cycle, tariffs, interest) are real but manageable and largely already in the numbers. The genuine open risk is managerial, not operational: a brand-new team steering a serial acquirer whose incentives point toward buybacks and adjusted-EPS optics rather than returns on the next dollar of capital.

9. Risk Analysis (Risk Matrix)

The two risks that matter most are #1 and #2, and they are correlated: the whole valuation rests on repeatable low-double-digit EPS growth, which requires both ≥3% organic and a repeatable buyback — and if organic stalls, the temptation to lever further into buybacks (raising #2) grows. #3 (tax) is an underappreciated swing factor. Catastrophic loss risk is remote given the investment-grade balance sheet and diversified, non-faddish revenue.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At ~$62.65, Fortive carries a market cap of ~$17.9B and EV of ~$21.0B. On TTM figures that is ~17.0x EV/EBITDA, ~4.4x EV/Sales, and a 32.9x GAAP P/E — the last badly distorted by purchase-amortization (GAAP diluted EPS was only $1.73). The economically meaningful gauge is forward adjusted P/E ≈ 21x on the $2.90–$3.00 FY2026 adjusted-EPS guide (trailing adjusted P/E ~23x on $2.71). FCF of ~$930M is a ~4.4% FCF yield on EV / ~5.2% on market cap.

Comp set (quality multi-industrial / instruments-plus-software compounders), TTM:

Two things fall out. First, on EV/EBITDA Fortive is not an outlier — 17.0x sits squarely in the 14.7–17.0x peer cluster (below only AME; ROP’s 15.0x is optically low because its adjusted framework strips enormous amortization). Second, on forward adjusted P/E (~21x) Fortive screens at the low end of the compounder set (ROP, VLTO, AME, XYL, STE generally low-20s to high-20s). The market is paying a full-but-not-extreme multiple, and less than for the acknowledged best-in-class compounders.

The own-history percentile flags — read critically. AZI’s valuation index shows FTV at the 99.94th percentile on both P/E and P/S — “richest-ever.” Both are contaminated: the Ralliant spin shrank the sales base ~28%, mechanically jumping P/S; and low post-spin GAAP EPS (heavy amortization) inflates the P/E percentile. The cleaner read is P/B at the 79th percentile — “rich, but not extreme” — consistent with the forward-P/E and EV/EBITDA evidence. (Note: tangible book is negative, so book-based reads are goodwill-laden.)

Embedded expectations. At ~21x forward adjusted EPS and ~17x EBITDA on a 2–3% organic grower, the market is underwriting the algorithm, not the top line: ~2–3% core + ~50–100 bps/yr margin expansion → ~mid-single-digit EBITDA growth, compounded with a ~5%/yr reduction in share count to produce low-double-digit adjusted-EPS growth, sustained for years, with no multiple compression. The embedded question is therefore not “will it grow revenue” but “is the buyback-driven half of the EPS algorithm repeatable?” — given ~$930M FCF, 2.4x gross leverage, and a ~3.0x practical ceiling, the recent ~$2B/yr repurchase pace is not obviously durable (Interpretation).

Scenarios (illustrative; explicit assumptions; not a target):

• Bear: organic fades to ~1–2%; margin expansion stalls; buyback halves as leverage caps out → adjusted-EPS growth decays to mid-single-digit and the multiple de-rates toward the 13–15x EV/EBITDA / ~16–17x forward P/E peer floor. Meaningful downside.
• Base: ~3% organic, 50–100 bps/yr margin, ~4–5% annual share shrink → ~9–11% adjusted-EPS growth; multiple broadly holds (~20–21x fwd / ~16–17x EBITDA) → the stock roughly compounds with earnings.
• Bull: organic accelerates to 4–5% (data-center Fluke, software/AI attach, healthcare-capital recovery), margin +100 bps, buyback sustained → low-to-mid-teens EPS growth and a re-rating toward AME/VLTO (18–20x EBITDA / mid-20s forward P/E).

Verdict. Fairly-to-fully valued — priced for the quality-compounder algorithm to keep delivering, but not a valuation outlier on the metrics that matter. The “richest-ever” percentile screens overstate the case; the honest richness is that a ~2–3% organic grower is being paid a ~21x forward multiple leaning heavily on repeatable buybacks and uninterrupted margin delivery. No price target.

11. Variant Perception

Consensus. The prevailing view is that post-spin “New Fortive” is a cleaner, higher-margin, more-recurring quality compounder that deserves a compounder multiple — and that three consecutive beats, double-digit adjusted-EPS growth, and a >10% share-count reduction validate an ongoing re-rating. Sell-side engagement is constructive, focused on data-center Fluke upside and margin cadence rather than on demand risk. Consensus is, in short, long the re-rating.

Strongest bull case. The quality upgrade is real, not cosmetic: ~29% Q1 adjusted-EBITDA margin, recurring revenue outgrowing total in both segments, software growing ahead of the company, and an intact FBS margin engine. The forward legs are credible — Fluke’s data-center O&M attach, ServiceChannel/Provation AI, and an inflecting healthcare-capital cycle — and, critically, Fortive is cheaper on forward adjusted P/E (~21x) than ROP, VLTO, AME, XYL, and STE. If organic durably reaches 3–4% while buybacks and margin persist, low-double-digit EPS growth plus a re-rate toward best-in-class peers is a genuine outcome. The bull says the market is underpaying for a compounder still discounted for the spin.

Strongest bear case. It is a ~2–3% organic grower dressed as a compounder, and the headline “double-digit EPS growth” is substantially financial engineering: buybacks funded by rising leverage that isn’t repeatable at ~$930M FCF once the ~3.0x ceiling is reached. GAAP EPS is only $1.73 (33x GAAP) with heavy amortization masking economics and negative tangible equity. Fluke (~40%) is late-cycle; healthcare capital is structurally pressured; the tax rate is unsustainably low. And the stock is at its post-spin high after a +36% run, so the easy re-rating is spent. Strip the buyback and you own a mid-single-digit EPS grower at ~21x.

The 3–5 assumptions that matter (with falsification):

1. Organic durably ≥3% vs structurally ~2%. Falsify bull: two consecutive quarters of sub-2% normalized (ex-selling-days) core. Falsify bear: sustained ~4%+ normalized core.
2. Margin algorithm (50–100 bps/yr) holds while reinvesting. Falsify: flat/declining adjusted-EBITDA margin ex-FX for two quarters.
3. Buyback-driven EPS growth is repeatable, not leverage-capped. Falsify bull: repurchase pace halving as gross leverage exceeds ~3.0x. Falsify bear: continued ~5%+ annual share shrink with stable leverage.
4. Software/AI attach materially lifts recurring mix/pricing. Falsify: recurring growth converges to total.
5. Tax rate stays sub-15%. Falsify: guidance to a low-20s rate — a ~12–15% EPS hit.

Factor-positioning read (integrated, labeled). The tape is a genuine tension. FactorsToday shows a chronic long-term underperformer — 10-yr +7.9%/yr with a −52.6% max drawdown, 5-yr +4.0%/yr, 3-yr +5.0%/yr — that has rallied sharply of late (+18% over 1yr; ~+14% over 6 months). But the factor loadings do not describe a momentum stock: in the Base+Sector model (r² 0.49) Fortive carries negative Momentum (~−0.22) and negative Growth (~−0.28), with mild-positive Value, Quality, DividendYield and SmallSize. Interpretation: the +36% move is a mean-reversion re-rating off a washed-out, forced-selling spin low — not a crowded momentum trade (the 12-1m momentum signal is still negative because the lookback spans the spin drop). So momentum-crowding risk is low by loading; the more relevant risk is that consensus has already priced the compounder narrative (~21x forward) before ~3% organic proves durable, extrapolating post-spin beats partly flattered by extra selling days and easy comps. Factor-similar peers (NDSN, IEX, AIT, DOV) confirm the honest comp set is the quality multi-industrial cluster — where FTV is priced roughly in line to slightly cheap, not offside. The pivotal, falsifiable fact for the next few quarters is simply whether normalized organic growth holds ≥3%.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the true recurring-revenue percentage and net-revenue-retention by segment? Management claims “~50% recurring”; the 10-K discloses only services = 20%. The gap is the software/consumable definition — unverified.
2. Is the sub-12% effective tax rate sustainable under OBBBA and OECD Pillar Two, or does it normalize toward the low-20s (a 12–15% EPS hit)?
3. Is the ~$2B/yr buyback pace durable once leverage approaches the ~3.0x practical ceiling and Ralliant proceeds are exhausted?
4. Will the restarted M&A engine show price discipline under a brand-new team with no ROIC pay hurdle, or repeat the 4–6x-sales deals that pushed consolidated returns to WACC?
5. How large and how durable is the data-center Fluke opportunity — a genuine organic accelerant, or a narrative flatter?
6. Does AI disintermediate or augment the vertical-software portfolio (Accruent/ServiceChannel/Provation/Gordian)?

14. What Must Be True

For the bull case (own it here at ~21x forward):

• Normalized organic growth must durably reach and hold ≥3–4% — the data-center Fluke pull-through and software/AI attach must show up in the organic rate, not just the narrative. Falsification test: two consecutive quarters of sub-2% normalized (ex-selling-days) core growth.
• The 50–100 bps/yr margin algorithm and ~5%/yr share shrink must both persist to deliver low-double-digit EPS growth, and the tax rate must not normalize. Falsification test: adjusted-EBITDA margin flat/down ex-FX for two quarters, or a guided move to a low-20s tax rate, or the buyback pace halving as leverage exceeds ~3.0x.

For the bear case (avoid / short-of-quality):

• Normalized organic must stall below 2% while the buyback becomes leverage-capped and the tax rate normalizes — exposing a mid-single-digit EPS grower at a low-double-digit-grower’s multiple, prompting de-rating toward the 15–17x EV/EBITDA peer floor. Falsification test: sustained ~4%+ normalized core growth with continued ~5% share shrink at stable leverage — which would validate, not break, the compounder thesis.

The two cases share one pivot: normalized organic growth ≥3%. Above it, the algorithm compounds and the multiple is defensible; below it, the stock is a financially-engineered EPS story paying a quality price. Everything in the valuation leans on that single, quarterly-observable number.

APPENDIX A — Standard Diligence Questionnaire

Fortive Corporation (NYSE: FTV) — supplemental to the research memo. Report date 2026-07-04. Continuing-operations (“New Fortive”/RemainCo) basis unless noted; Precision Technologies was spun off as Ralliant on June 28, 2025.

General

What thoughtful questions have other investors asked about this company? The dominant questions post-spin: (1) Is “New Fortive” genuinely a higher-quality compounder that deserves a compounder multiple, or a slow-grower flattered by a clean-up spin? (2) How much of the double-digit adjusted-EPS growth is organic versus buyback? (3) Is the data-center Fluke opportunity real and durable? (4) Does AI threaten the vertical-software portfolio? (5) Is the sub-12% tax rate sustainable? Sell-side engagement (Wolfe, Barclays, Citi, RBC, JPMorgan, Baird, Seaport) has centered on data-center Fluke upside and margin cadence rather than demand risk.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Roughly mid-cycle, tilted toward a low on volume: FY2025 volume was negative (−0.6%), with the entire +1.7% core coming from price. Fluke (~40%) is short-cycle-industrial-exposed and healthcare-capital demand (Sterrad equipment) troughed in 2025 — both suggest volumes are nearer a cyclical low than high. Margins, by contrast, are near a structural high and guided higher (FBS).

Driven by the external environment or internal actions? Both. Revenue is externally driven (industrial short-cycle, hospital capital budgets); the per-share earnings growth is overwhelmingly internal — buybacks, FBS margin expansion, and a low tax rate.

How stable are revenues? Moderately stable and improving in quality: ~20% is contracted services, a growing subscription-software base ($840.7M RPO), and consumable pull-through (Sterrad cassettes, Landauer dosimetry). But ~40% (Fluke) is transactional and short-cycle.

Outlook for products/services; how big is the market? Mature niches with modest secular growth (multimeters ~6%, low-temp sterilization ~9% for VHP, IWMS software ~5–7%, dosimetry low-single-digit). Aggregate organic ceiling is ~mid-single-digit. Global, but 60% North America.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable in the defensible niches (Fluke, ASP, Landauer — brand/regulatory barriers); more competitive in vertical software (IWMS/EHSQ), where Fortive’s moat is weakest and AI raises the disruption question.

How profitable is the business (ROIC, ROE)? Reported ROIC ~5.3%, ROE ~8.5% — both understated by ~$9.5B of acquisition goodwill (81% of assets). Cash-adjusted ROIC (amortization added back) ~9.2%, roughly at WACC. On tangible/incremental capital the businesses earn very high returns (2.5% capex, negative working capital); the drag is the price paid, not the operations.

How profitable is the industry — competitors, barriers? Attractive oligopolistic/branded niches. Fluke leads handheld test; ASP is ~27.6% of a ~45% top-three sterilization oligopoly (with STERIS, Getinge); Landauer is top-two in dosimetry. Barriers: brand (Fluke), FDA + installed base (ASP), regulation + system-of-record (Landauer), SaaS switching costs (software).

Can the business be easily understood? Yes, at the segment level — instruments, software, sterilization, dosimetry. The complexity is accounting (amortization, adjusted metrics, spin recasts), not the business model.

Can it be undermined by foreign low-cost labor? Limited. Fluke faces low-cost Asian meter brands but is insulated by brand/safety-criticality; ASP/Landauer/software are regulation- and integration-protected. “Made-in-region” (India/China) initiatives are a tailwind, not a threat.

Do brands matter? Decisively for Fluke (the single strongest moat); meaningfully for Sterrad and Landauer as trusted, validated systems; less so for software (feature/integration competition).

Nature of competition; customers’ switching costs? Highest at ASP (FDA-validated cycles + consumable lock-in) and Landauer (compliance system of record); high for Fluke (brand/habit); moderate for software (data/workflow); the switching-cost story is real but uneven.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the Fluke, Sterrad, and Landauer brands and installed bases, plus internally-developed software, are worth far more than carried; conversely the balance sheet is dominated by acquisition goodwill.

Off-balance-sheet liabilities? None material flagged beyond ordinary operating leases; no defined-benefit pension of consequence; litigation ordinary-course.

How conservative is the accounting? Mixed. Conservative in not adding back SBC to adjusted EPS (a plus). Aggressive-adjacent in the reliance on an amortization add-back and a very low tax rate to present the earnings power; continuing-vs-discontinued spin accounting requires care. GAAP is heavily depressed by amortization.

How CapEx-hungry? Very asset-light — capex $105.1M, 2.5% of sales.

Capital Allocation & Management

How much FCF, and how is it used? ~$930M continuing FCF. Priority order: modest organic reinvestment → bolt-on M&A (restarting) → buybacks (the dominant use: $1.61B in 2025) → a tiny growing dividend. Philosophy is Danaher-heritage: buybacks and reinvestment over payout.

Significant acquisitions recently? No — a three-year M&A pause (2023–25 cash for deals $95.8M / $3.6M / $25.7M) during the spin. Restarting: June-2026 ASP/UV Smart majority stake (terms undisclosed); new corp-dev head installed.

Buying back shares? Aggressively — >10% of shares retired since the July-2025 spin; 341.2M → 313.4M in 2025 at ~$53.67 average.

Issuing large amounts of stock to insiders? SBC $116.8M (+30% YoY, separation-driven) — material but buybacks more than offset it; net share count fell sharply.

Compensation policy of directors/management? Bonus = 60% Adjusted EPS / 20% FCF / 20% Core Revenue Growth; PSUs = 60% relative TSR / 40% Core Revenue Growth. No return-on-capital metric anywhere — a governance flag for a self-described capital-allocation-disciplined serial acquirer. Insider ownership <1% as a group.

Motivations of management? New team (CEO Soroye, CFO Okerstrom, both post-spin). Incentives point toward adjusted-EPS optics and buybacks. The one positive alignment signal is the CFO’s ~$1M open-market purchase at $47.03 (Aug 2025).

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — U.S. C-corp, common stock, NYSE-listed, standard 1099 reporting.

Dividend policy? Small and growing — ~$0.24/year, ~0.4% yield, ~17% of adjusted EPS. Deliberately de-emphasized in favor of buybacks.

How profitable is the business? 63.5% gross margin, ~26% adjusted operating margin, ~30% adjusted EBITDA margin, 100%+ FCF conversion — high operating profitability; consolidated returns on capital only ~WACC due to goodwill.

Is net income diverging from cash from operations? Yes, favorably — OCF ($1,035.7M continuing) exceeds GAAP continuing net income ($532.7M), the gap being non-cash D&A ($437.6M) and SBC ($116.8M). Cash quality is strong; no working-capital earnings mirage.

Risks & Downside

What would cause the stock to decline? Normalized organic growth stalling below ~2%; the buyback pace slowing as leverage hits ~3.0x; the tax rate normalizing; multiple de-rating from ~21x forward as the compounder narrative fades; a value-destructive M&A restart.

Risk of a catastrophic loss? Low. Investment-grade balance sheet (2.4x net leverage, 9.6x coverage), $930M FCF, diversified non-faddish revenue, no single-product dependency.

Chance of a total loss? Remote — this is a profitable, cash-generative, investment-grade company; the realistic risk is under-performance/de-rating, not impairment.

Recent News & Events

Has the business environment changed recently? Materially — the June-2025 Ralliant spin, a full CEO/CFO reset, an aggressive post-spin buyback, a May-2026 refinancing at higher coupons, and a restarting M&A engine (UV Smart, June 2026). Healthcare-capital demand troughed in 2025 and is improving; tariffs are a countermeasured GM headwind dissipating into Q4’26.

Significant acquisitions? ASP/UV Smart majority stake (June 2026) — small, terms undisclosed; the first deal of the restarted engine.

Change in accounting policies? No policy change, but heavy spin-driven continuing-vs-discontinued recasting through 2025 — use continuing-operations figures throughout.

Recent changes — new markets, facilities, management? New management team; European STERRAD Ultra GI launch; Fluke CertiFiber Max data-center push; made-in-region India/China initiatives.

APPENDIX B — Source Appendix

Fortive Corporation (NYSE: FTV) — report date 2026-07-04. Primary sources prioritized. Facts reconciled to filings; third-party aggregated data (ROIC.ai, AZI, FactorsToday) cross-checked against primary documents and labeled.

Primary — SEC filings (EDGAR, CIK 0001659166)

Primary — company disclosures

• Q4/FY2025 earnings release & presentation (2026-02-04) — adjusted-EPS bridge ($1.59 GAAP → $2.71 adjusted), FY2026 guide ($2.90–$3.00, 2–3% core, ~$4.3B revenue).
• Q1 2026 earnings call transcript (2026-04-30) — normalized organic (~3.5%), FAL/ServiceChannel leadership, Fluke data-center (CertiFiber Max), tariff cadence, buyback pace, M&A restart.
• Q4 2025 earnings call transcript (2026-02-04) — FY2026 framework, buyback ~600 bps EPS tailwind, AI-defensibility framing, healthcare-capital recovery.
• Q3 2025 earnings call transcript (2025-10-29) — first standalone RemainCo quarter, “Fortive Accelerator” strategy.
• Investor Day (2025-06-10) — “~50% recurring revenue” claim (management definition; unverified in 10-K), 50–100 bps/yr margin-expansion framework.
• Fortive corporate & IR site (fortive.com) — segment/brand descriptions, FBS.

Industry & competitive (third-party)

• Grand View Research — digital multimeter market (~$1.05B 2024 → ~$1.77B 2033) and low-temperature sterilization market (~$5.07B by 2030).
• SelectHub / FacilitiesDive — IWMS market sizing (~$9.8B 2023 → ~$12.1B 2027).
• MarketsandMarkets / Grand View — advanced-sterilization share (ASP ~27.6%; STERIS/Getinge/ASP ~45% top-three).
• Radetco — radiation-dosimetry market concentration (top-five ~55%).
• Trade press (TestMeterPro and similar) — Fluke category leadership context.
• Peer competitor context — Keysight, Tektronix, Klein Tools, HIOKI (test); IBM Maximo, Nuvolo, Brightly/Siemens, eMaint, Fiix, MaintainX (software); Honeywell, MSA Safety, Dräger (gas detection); STERIS, Getinge (sterilization); Mirion, Thermo Fisher (dosimetry).

Quantitative data & cross-checks (third-party aggregated — reconciled to filings)

• ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/credit/valuation ratios, enterprise value, per-share data, and earnings-call transcripts (multi-year). Used for ratio trends and EV; reconciled to the 10-K.
• AZI valuation index — own-history percentile ranks (P/E 99.94th, P/S 99.94th, P/B 79.1st, composite 93.0) — flagged as spin-contaminated on P/E and P/S; P/B treated as the cleaner read.
• AZI price CSV (azitrading.com) — five-year split/dividend-adjusted OHLCV for the Event Map; note spin-adjustment of pre-June-2025 prices.
• FactorsToday (factorstoday.com/api) — factor loadings (negative Momentum/Growth; mild Value/Quality/DividendYield/SmallSize), risk-adjusted leaderboard (10-yr +7.9%/yr, −52.6% max DD; 5-yr +4.0%/yr; 1-yr +18%), factor-similar peers (NDSN, IEX, AIT, DOV).
• Comp multiples (ROIC.ai, TTM) — AME, ROP, VLTO, DOV, IEX, XYL, STE.

Notes on reliability

Management commentary (guidance, “~50% recurring,” data-center opportunity, AI-defensibility) is treated as hypothesis, not evidence and is labeled as such throughout. Where the ROIC.ai aggregator’s reported ROIC (~5.3%) differed from a normalized build, the filing-based calculation was used and the tangible-capital reframe noted. All valuation percentiles are own-history, never cross-sectional. No price target or buy/sell recommendation appears anywhere outside the clearly-labeled “Claude’s Take” block.